Recent Analysts’ Ratings Updates for Biogen (BIIB)

Several analysts have recently updated their ratings and price targets for Biogen (NASDAQ: BIIB):

• 11/3/2025 – Biogen was given a new $157.00 price target on by analysts at Tudor Pickering.
• 11/3/2025 – Biogen had its price target raised by analysts at Sanford C. Bernstein from $155.00 to $157.00. They now have a “market perform” rating on the stock.
• 11/1/2025 – Biogen was downgraded by analysts at Wall Street Zen from a “strong-buy” rating to a “buy” rating.
• 10/31/2025 – Biogen had its price target raised by analysts at Wells Fargo & Company from $140.00 to $155.00.
• 10/31/2025 – Biogen had its price target raised by analysts at Wedbush from $135.00 to $143.00. They now have a “neutral” rating on the stock.
• 10/31/2025 – Biogen had its price target raised by analysts at Guggenheim from $165.00 to $185.00.
• 10/31/2025 – Biogen had its price target raised by analysts at BMO Capital Markets from $128.00 to $150.00.
• 10/31/2025 – Biogen had its price target lowered by analysts at Royal Bank Of Canada from $217.00 to $210.00. They now have an “outperform” rating on the stock.
• 10/31/2025 – Biogen had its price target lowered by analysts at Robert W. Baird from $255.00 to $250.00.
• 10/24/2025 – Biogen was upgraded by analysts at Weiss Ratings from a “sell (d+)” rating to a “hold (c-)” rating.
• 10/14/2025 – Biogen had its price target raised by analysts at Wedbush from $129.00 to $135.00. They now have a “neutral” rating on the stock.
• 10/10/2025 – Biogen had its price target raised by analysts at Morgan Stanley from $144.00 to $149.00. They now have an “equal weight” rating on the stock.
• 10/8/2025 – Biogen had its “sell (d+)” rating reaffirmed by analysts at Weiss Ratings.
• 10/8/2025 – Biogen had its price target lowered by analysts at Royal Bank Of Canada from $219.00 to $217.00. They now have an “outperform” rating on the stock.
• 10/6/2025 – Biogen had its price target raised by analysts at Rothschild & Co Redburn from $149.00 to $150.00. They now have a “neutral” rating on the stock.
• 9/28/2025 – Biogen was upgraded by analysts at Wall Street Zen from a “buy” rating to a “strong-buy” rating.
• 9/27/2025 – Biogen had its “sell (d+)” rating reaffirmed by analysts at Weiss Ratings.
• 9/25/2025 – Biogen is now covered by analysts at Jefferies Financial Group Inc.. They set a “buy” rating and a $190.00 price target on the stock.
• 9/24/2025 – Biogen had its “neutral” rating reaffirmed by analysts at Citigroup Inc..
• 9/24/2025 – Biogen had its “outperform” rating reaffirmed by analysts at William Blair.
• 9/24/2025 – Biogen had its “hold” rating reaffirmed by analysts at Needham & Company LLC.
• 9/20/2025 – Biogen was downgraded by analysts at Wall Street Zen from a “strong-buy” rating to a “buy” rating.
• 9/12/2025 – Biogen had its price target raised by analysts at Piper Sandler from $115.00 to $118.00. They now have a “neutral” rating on the stock.
• 9/5/2025 – Biogen was upgraded by analysts at Wall Street Zen from a “buy” rating to a “strong-buy” rating.
• 9/4/2025 – Biogen had its “hold” rating reaffirmed by analysts at Needham & Company LLC.

Insider Buying and Selling at Biogen

In other news, insider Priya Singhal sold 517 shares of the firm’s stock in a transaction on Tuesday, September 2nd. The stock was sold at an average price of $133.55, for a total value of $69,045.35. Following the completion of the transaction, the insider owned 5,772 shares in the company, valued at $770,850.60. This trade represents a 8.22% decrease in their ownership of the stock. The sale was disclosed in a filing with the SEC, which is available through the SEC website. 0.18% of the stock is currently owned by corporate insiders.

Biogen Inc discovers, develops, manufactures, and delivers therapies for treating neurological and neurodegenerative diseases in the United States, Europe, Germany, Asia, and internationally. The company provides TECFIDERA, VUMERITY, AVONEX, PLEGRIDY, TYSABRI, and FAMPYRA for multiple sclerosis (MS); SPINRAZA for spinal muscular atrophy; ADUHELM to treat Alzheimer’s disease; FUMADERM to treat plaque psoriasis; BENEPALI, an etanercept biosimilar referencing ENBREL; IMRALDI, an adalimumab biosimilar referencing HUMIRA; FLIXABI, an infliximab biosimilar referencing REMICADE; and BYOOVIZ, a ranibizumab biosimilar referencing LUCENTIS.